author-photo

Nancy Chan

Rutgers University

24

Papers

317

Citations

Citation Trend

Filter By

Papers (18) Sort By

Journal Conference Others

A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies

2021 Cancer Chemotherapy and Pharmacology
Show All
- Source
- Cite
- Save
Citations (0)
Breast intraductal nanoformulations for treating ductal carcinoma in situ II: Dose de-escalation using a slow releasing/slow bioconverting prodrug strategy.

2021 Drug Delivery and Translational Research
Show All
- Source
- Cite
- Save
Citations (0)
Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer.

2021 Case Reports in Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens.

2021 Breast Cancer Research and Treatment
Show All
- Source
- Cite
- Save
Citations (0)
A phase Ib study of troriluzole (BHV-4157) in combination with nivolumab.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Abstract OT1-02-01: Phase I trial of bicalutamide and ribociclib in androgen receptor-positive triple negative breast cancer

2019 Cancer Research
Show All
- Source
- Cite
- Save
Citations (7)
Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration

2019 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (21)
Abstract A074: Correlation of homologous recombination deficiency (HRD) status by BROCA-HR sequencing with response to combination cediranib and olaparib in relapsed ovarian cancer

2019 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (0)
NCI9782: A phase 1 study of talazoparib in combination with carboplatin and paclitaxel in patients with advanced solid tumors.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
A phase 2 biomarker trial of combination cediranib and olaparib in relapsed platinum (plat) sensitive and plat resistant ovarian cancer (ovca).

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (10)